XERS

4.88

5.24% -0.27

Handel nachbörslich: 4.82 -0.06 -1.23%

Xeris Biopharma Holdings Inc (XERS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$5.15

Offen:

$4.95

24-Stunden-Volumen:

2.80M

Relative Volume:

1.10

Marktkapitalisierung:

$751.23M

Einnahmen:

$181.41M

Nettoeinkommen (Verlust:

$-59.56M

KGV:

-11.62

EPS:

-0.42

Netto-Cashflow:

$-38.83M

1W Leistung:

-13.32%

1M Leistung:

+32.25%

6M Leistung:

+63.76%

1J Leistung:

+134.62%

1-Tages-Spanne:

$4.8442

$5.05

1-Wochen-Bereich:

$4.8442

$5.70

52-Wochen-Spanne:

$1.69

$6.07

Xeris Biopharma Holdings Inc Stock (XERS) Company Profile

Firmenname

Xeris Biopharma Holdings Inc

Sektor

Healthcare (1174)

Branche

Biotechnology (678)

Telefon

844-445-5704

Adresse

1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL

Mitarbeiter

Twitter

@XerisPharma

Nächster Verdiensttermin

2024-12-08

Neueste SEC-Einreichungen

XERS's Discussions on Twitter

Vergleichen Sie XERS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
XERS Xeris Biopharma Holdings Inc	4.88	751.23M	181.41M	-59.56M	-38.83M	-0.42
VRTX Vertex Pharmaceuticals Inc	484.01	124.29B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	610.64	68.39B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	590.06	35.99B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	262.16	33.93B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	264.32	28.47B	3.81B	-644.79M	-669.77M	-6.24

Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-11-11	Herabstufung	Piper Sandler	Overweight → Neutral
2024-03-28	Eingeleitet	Oppenheimer	Outperform
2023-08-28	Eingeleitet	Craig Hallum	Buy
2022-10-21	Eingeleitet	Jefferies	Buy
2022-04-28	Eingeleitet	Craig Hallum	Buy
2021-11-17	Eingeleitet	SVB Leerink	Outperform
2021-10-29	Eingeleitet	H.C. Wainwright	Buy
2021-04-07	Fortgesetzt	RBC Capital Mkts	Outperform
2020-02-18	Eingeleitet	Piper Sandler	Overweight
2018-07-16	Eingeleitet	Jefferies	Buy
2018-07-16	Eingeleitet	Leerink Partners	Outperform
2018-07-16	Eingeleitet	RBC Capital Mkts	Outperform

Alle ansehen

Xeris Biopharma Holdings Inc Aktie (XERS) Neueste Nachrichten

Mar 31, 2025

AIGH Capital Management LLC Purchases 389,192 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - MarketBeat

Mar 31, 2025

Xeris Biopharma reshuffles board, appoints new director By Investing.com - Investing.com Australia

Mar 28, 2025

Xeris Announces Changes to Its Board of Directors - Business Wire

Mar 28, 2025

Mar 27, 2025

Is Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5? - Insider Monkey

Mar 27, 2025

Mar 25, 2025

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Sold by Bank of New York Mellon Corp - Defense World

Mar 25, 2025

Mar 23, 2025

Don't Ignore The Insider Selling In Xeris Biopharma Holdings - simplywall.st

Mar 23, 2025

Connor Clark & Lunn Investment Management Ltd. Has $581,000 Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

Mar 23, 2025

Xeris Biopharma (NASDAQ:XERS) Stock Price Up 4.9% – Here’s Why - Defense World

Mar 23, 2025

Mar 22, 2025

Xeris Biopharma chief legal officer Beth Hecht sells $217,244 in stock - Investing.com Australia

Mar 22, 2025

Mar 21, 2025

Xeris Biopharma chief legal officer Beth Hecht sells $217,244 in stock By Investing.com - Investing.com South Africa

Mar 21, 2025

Xeris Pharmaceuticals stock hits 52-week high at $5.54 - Investing.com

Mar 21, 2025

Xeris Pharmaceuticals stock hits 52-week high at $5.54 By Investing.com - Investing.com South Africa

Mar 21, 2025

Mar 20, 2025

Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength? - Yahoo Finance

Mar 20, 2025

Xeris Biopharma (NASDAQ:XERS) Reaches New 52-Week High – Time to Buy? - Defense World

Mar 20, 2025

Mar 19, 2025

Xeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market Game - Insider Monkey

Mar 19, 2025

Xeris enters a whole new market for one of its main pharma offerings - Crain's Chicago Business

Mar 19, 2025

Is XERS Stock a Good Buy in 2025? Key Insights for Investors - Stocks Telegraph

Mar 19, 2025

Mar 18, 2025

12 Best Stocks to Invest in for a Stock Market Game - Insider Monkey

Mar 18, 2025

Xeris Biopharma gets FDA nod for Gvoke VialDx, teams with American Regent - Investing.com Australia

Mar 18, 2025

Mar 17, 2025

Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid - BioSpace

Mar 17, 2025

Xeris Biopharma Says US FDA Approves Gvoke VialDx for Diagnostic Use -March 17, 2025 at 08:33 am EDT - Marketscreener.com

Mar 17, 2025

Xeris Biopharma gets FDA nod for Gvoke VialDx, teams with American Regent By Investing.com - Investing.com South Africa

Mar 17, 2025

Breakthrough FDA Approval: Xeris' Novel Glucagon Solution Transforms Radiologic Diagnostics - Stock Titan

Mar 17, 2025

Mar 16, 2025

Xeris Biopharma: Low Risk, Low Excitement Solid Revenue Generator (NASDAQ:XERS) - Seeking Alpha

Mar 16, 2025

Investors Appear Satisfied With Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Prospects As Shares Rocket 34% - Simply Wall St

Mar 16, 2025

Xeris BiopharmaPossibly the best Pharma Stock - MSN

Mar 16, 2025

Mar 13, 2025

Analysts Set Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Target Price at $5.92 - Defense World

Mar 13, 2025

Mar 11, 2025

Will Xeris Biopharma's Financial Transformation Reach New Heights In 2025? - RTTNews

Mar 11, 2025

Xeris Biopharma (XERS) Expects to Ride the Wave of 30% Revenue Growth in 2025 - Markets Insider

Mar 11, 2025

Mar 10, 2025

What Are Expectations For Xeris Biopharma Holdings Inc (NASDAQ: XERS) In The Short Term? - Stocks Register

Mar 10, 2025

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 10, 2025

Analysts Issue Forecasts for Xeris Biopharma Q1 Earnings - Defense World

Mar 10, 2025

Mar 09, 2025

Piper Sandler Reaffirms Neutral Rating for Xeris Biopharma (NASDAQ:XERS) - Defense World

Mar 09, 2025

HC Wainwright Reaffirms Buy Rating for Xeris Biopharma (NASDAQ:XERS) - Defense World

Mar 09, 2025

Mar 08, 2025

Who Really Controls Xeris Biopharma? The Retail Investors’ Unseen Power - DSA

Mar 08, 2025

Principal Financial Group Inc. Grows Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

Mar 08, 2025

Rhumbline Advisers Purchases 7,408 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

Mar 08, 2025

Mar 07, 2025